Methods and cell lines for immortalization and monoclonal antibody production by antigen-stimulated B-lymphocytes
US4574116A · kind A · utility
Assignee
Inventors
Key dates
| Filing date | Jan 13, 1983 |
| Grant date | Mar 4, 1986 |
| Priority date | — |
| Expiry date | Jan 13, 2003 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY10S435/948
- WIPO fieldBiotechnology
- WIPO sectorChemistry
Abstract
Methods are provided for producing fusion partners which involve employing an immortalized human myeloma cell line sensitive to HAT and having an additional dominant selectable resistance marker and fusing the doubly marked human myeloma cells with a stable immortalized rodent myeloma cell line, desirably previously subjected to substantial chromosome damage, and isolating cells having a substantially complete chromosomal complement of the rodent cell and at least about one chromosome of the human cell having a gene expressing said resistance, thereby being resistant to a selective agent. The resulting heteromyeloma may be fused with high efficiency with human lymphocytes to produce monoclonal antibodies. The cell lines designated as A6 and 36 were deposited at the A.T.C.C. on Jan. 11, 1983 and given accession numbers CRL8192 and CRL8193, respectively.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.